Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Inducing Cytochrome P450 on the Efficacy of Clopidogrel in Patients With Reduced-Function CYP2C19 Polymorphisms Undergoing Percutaneous Coronary Intervention.

Next Previous
Trial Profile

The Effect of Inducing Cytochrome P450 on the Efficacy of Clopidogrel in Patients With Reduced-Function CYP2C19 Polymorphisms Undergoing Percutaneous Coronary Intervention.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel (Primary) ; Hypericum
  • Indications Major depressive disorder; Thrombosis
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms INDUCE-it

Most Recent Events

  • 05 Oct 2017 Biomarkers information updated
  • 17 Jan 2013 Planned End Date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
  • 06 Oct 2011 Planned end date changed from 1 Sep 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top